There was recently an article in the news about mice who were flown on the International Space Station who resisted the normal loss of muscle mass associated with weightlessness as a result of receiving a drug containing a new myostatin inhibitor. The mice not only resisted muscle loss, they gained muscle and bone density, developing twice the amount of muscle as normal mice. The journal article describing the study calls the myostatin inhibitor "A decoy receptor (ACVR2B/Fc) consisting of the extracellular, ligand-binding domain of ACVR2B fused to an immunoglobulin Fc domain." The journal article goes on to say the drug "can induce significant muscle growth when given systemically to wild type mice. Indeed, by blocking both ligands, this decoy receptor can induce significantly more muscle growth than other MSTN inhibitors, and at high doses, ACVR2B/Fc can induce over 50% muscle growth in just 2 wk. Moreover, because this decoy receptor can block not only MSTN but also activin A, systemic administration of ACVR2B/Fc can also lead to significant increases in bone density. The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility."
It seems the pharmaceutical companies, as well as the peptide "research suppliers" should be all over this.
It seems the pharmaceutical companies, as well as the peptide "research suppliers" should be all over this.
